cedelizumab
mAbexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- T-cell surface antigen CD4INHIBITOR
CD4 inhibitor
It causes consistent blockade of cell-surface CD4 molecules on T lymphocytes blocking the activation of T lymphocytes (no depletion of T cells). Regulation of the immune response.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108266 ↗
Also known as
- cedelizumab
- orthoclone okt4 a
- rwj-49004